Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

Blood

Volumn 121, Issue 18, 2013, Pages 3666-3674

  Trinh, Diane L ^a,b   Scott, David W ^a   Morin, Ryan D ^a,c   Mendez Lago, Maria ^a   An, Jianghong ^a   Jones, Steven J M ^a,b,c   Mungall, Andrew J ^a   Zhao, Yongjun ^a   Schein, Jacqueline ^a   Steidl, Christian ^a,d   Connors, Joseph M ^a   Gascoyne, Randy D ^a,d   Marra, Marco A ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FORKHEAD TRANSCRIPTION FACTOR; LACTATE DEHYDROGENASE; MYC PROTEIN; PREDNISONE; PROTEIN 14 3 3; PROTEIN BCL 2; RITUXIMAB; TRANSCRIPTION FACTOR FKHR; VINCRISTINE; FOXO1 PROTEIN, HUMAN;

ADULT; AGED; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; B-CELL LYMPHOMA CELL LINE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; EXON; FEMALE; FOLLICULAR LYMPHOMA; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ADOLESCENT; CELL STRAIN HEK293; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENETIC PREDISPOSITION TO DISEASE; HEK293 CELLS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; PROGNOSIS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879734857     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-479865     Document Type: Article

References (41)

1. Maiese K, Chong ZZ, Shang YC, Hou JA. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev. 2009;29(3):395-418.
2. Reagan-Shaw S, Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol. 2007;224(3):360-368. (Pubitemid 47575672)
3. Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008;14(5):219-227.
4. Maiese K, Chong ZZ, Hou J, Shang YC. The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol. 2009;665:242-260.
5. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci. 2007;120(Pt 15):2479-2487. (Pubitemid 47323857)
6. Paik J-H, Kollipara R, Chu G, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128(2):309-323. (Pubitemid 46123514)
7. Xie L, Ushmorov A, Leithäuser F, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119(15):3503-3511.
8. Naka K, Hoshii T, Muraguchi T, et al. TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463(7281):676-680.
9. Sykes SM, Lane SW, Bullinger L, et al. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011;146(5):697-708.
10. Dengler HS, Baracho GV, Omori SA, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9(12):1388-1398.
11. Yusuf I, Zhu X, Kharas MG, Chen J, Fruman DA. Optimal B-cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. Blood. 2004;104(3):784-787. (Pubitemid 38970574)
12. Su Y-W, Hao Z, Hirao A, et al. 14-3-3sigma regulates B-cell homeostasis through stabilization of FOXO1. Proc Natl Acad Sci USA. 2011;108(4):1555-1560.
13. Amin RH, Schlissel MS. Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat Immunol. 2008;9(6):613-622. (Pubitemid 351712632)
14. Chen J, Limon JJ, Blanc C, Peng SL, Fruman DA. Foxo1 regulates marginal zone B-cell development. Eur J Immunol. 2010;40(7):1890-1896.
15. Hillion S, Rochas C, Youinou P, Jamin C. Signaling pathways regulating RAG expression in B lymphocytes. Autoimmun Rev. 2009;8(7):599-604.
16. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303.
17. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
18. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. (Pubitemid 30082188)
19. Rosenwald A, Wright G, Chan WC, et al Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
20. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282. (Pubitemid 38029949)
21. Lenz G, Wright G, Dave SS, et al Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
22. Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Prognostic biomarkers in malignant lymphomas. Leuk Lymphoma. 2010;51(suppl 1):11-19.
23. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
24. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861. (Pubitemid 46348180)
25. Obsil T, Obsilova V. Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene. 2008;27(16):2263-2275. (Pubitemid 351501778)
26. Guo S, Rena G, Cichy S, He X, Cohen P, Unterman T. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem. 1999;274(24):17184-17192.
27. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857-868. (Pubitemid 29165088)
28. Rena G, Prescott AR, Guo S, Cohen P, Unterman TG. Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochem J. 2001;354(Pt 3):605-612. (Pubitemid 32269724)
29. Nakae J, Barr V, Accili D. Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J. 2000;19(5):989-996. (Pubitemid 30119824)
30. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors: regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta. 2011;1813(11):1938-1945.
31. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J. 2004;380(Pt 2):297-309. (Pubitemid 38788101)
32. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274(24):17179-17183.
33. Brunet A, Kanai F, Stehn J, et al. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol. 2002;156(5):817-828. (Pubitemid 34839865)
34. Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 1999;96(13):7421-7426. (Pubitemid 29299677)
35. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 2001;20(40):5736-5746. (Pubitemid 32928111)
36. Borkhardt A, Repp R, Haas OA, et al. Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene. 1997;14(2):195-202. (Pubitemid 27068305)
37. Cahill CM, Tzivion G, Nasrin N, Ogg S, Dore J, Ruvkun G, Alexander-Bridges M. Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14-3-3-dependent and 14-3-3-independent pathways. J Biol Chem. 2001;276(16):13402-13410.
38. Zhang B, Tomita Y, Ch'ng E, et al. Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. Ann Surg Oncol. 2009;16(7):1925-1937.
39. Kim JH, Kim MK, Lee HE, et al. Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer. Mod Pathol. 2007;20(8):835-842. (Pubitemid 47077265)
40. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2012;2(1):104-115.
41. Chin S-F, Daigo Y, Huang H-E, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol. 2003;56(5):275-279. (Pubitemid 37243919)